...
首页> 外文期刊>Biotechnology & Biotechnological Equipment >Soluble expression and purification of heparinase I in Escherichia coli using a hexahistidine-tagged small ubiquitin-like modifier as a fusion partner
【24h】

Soluble expression and purification of heparinase I in Escherichia coli using a hexahistidine-tagged small ubiquitin-like modifier as a fusion partner

机译:肝素酶I在大肠杆菌中的可溶性表达和纯化,使用带有六组氨酸标签的小泛素样修饰剂作为融合伴侣

获取原文
   

获取外文期刊封面封底 >>

       

摘要

ABSTRACT Heparinase has an important application in the preparation of low-molecular-weight heparins and the deheparinization of heparin-treated blood. To increase the soluble expression of heparinase I (HepI) in recombinant Escherichia coli , the hepA gene (coding for HepI) from Flavobacterium heparinum was obtained through chemical synthesis and fused with the gene encoding hexahistidine, small ubiquitin-like modifier (SUMO), a flexible peptide linker (G 4 S) and a bovine enterokinase site (D 4 K). The constructed fusion protein (SUMO?¢????HepI) was expressed in E. coli BL21 (DE3), and then purified with Ni 2+ -chelating affinity chromatography. The fermentation conditions were optimized and the enzymatic properties were also analyzed. As the results showed, the recombinant SUMO?¢????HepI was successfully expressed in E. coli BL21 (DE3) and purified with affinity chromatography. The recombinant protein reached the highest soluble expression when the expression strain was induced by 0.6????mmol/L isopropyl ???2-D-thiogalactoside and grown at 30 ???°C with a shaking speed of 150 r/min for 9 h. The fusion protein could exhibit high enzyme activity without requirements of in vitro refolding and SUMO-tag releasing process, and the optimum enzyme activity was obtained at 30 ???°C, pH 7.0 and 10????mmol/L Ca 2+ in the reaction buffer. This work provided a novel simple approach for the soluble expression of HepI in E. coli , and might establish a foundation for the following production and application of HepI in the industry.
机译:摘要肝素酶在低分子量肝素的制备和肝素处理过的血液的脱肝素中具有重要的应用。为了增加肝素酶I(HepI)在重组大肠杆菌中的可溶性表达,通过化学合成从肝黄杆菌中获得了hepA基因(编码HepI),并将其与编码六组氨酸,小的泛素样修饰剂(SUMO),柔性肽接头(G 4 S)和牛肠激酶位点(D 4 K)。在大肠杆菌BL21(DE3)中表达所构建的融合蛋白(SUMOΔβΔHepI),然后用Ni 2+螯合亲和层析纯化。优化了发酵条件,并分析了酶性质。结果表明,重组SUMOΔβ-HepI在大肠杆菌BL21(DE3)中成功表达并用亲和层析纯化。当用0.6 5 mmol / L的异丙基2-D-硫代半乳糖苷诱导表达菌株并在30℃以150 r / min的振荡速度生长时,重组蛋白达到最高的可溶性表达。持续9小时。该融合蛋白无需体外重折叠和SUMO标签释放过程即可显示出高的酶活性,并且在30℃,pH 7.0和10 -6 mmol / L Ca 2+下可获得最佳的酶活性。在反应缓冲液中。这项工作为HepI在大肠杆菌中的可溶性表达提供了一种新颖的简单方法,并可能为随后的HepI的生产和工业应用奠定基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号